IWC
KLRS

Integrated Wealth Concepts’s Kalaris Therapeutics KLRS Stock Holding History

Integrated Wealth Concepts’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.4K Buy
+5,000
New +$26K ﹤0.01% 4072

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Integrated Wealth Concepts's KLRS Position: Q2 2026 in Review

Integrated Wealth Concepts opened a new position in Kalaris Therapeutics (KLRS) in Q2 2026: 5,000 shares worth $20.4K. The stake represents ﹤0.01% of the portfolio and ranks #4072 among its holdings.

57 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Integrated Wealth Concepts held 5,000 shares of Kalaris Therapeutics worth $20.4K as of Q2 2026.
  • Kalaris Therapeutics was a new Integrated Wealth Concepts position in Q2 2026.
  • Kalaris Therapeutics made up ﹤0.01% of Integrated Wealth Concepts's portfolio in Q2 2026, its #4072 holding.
  • 57 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Integrated Wealth Concepts's 13F filing for Q2 2026, filed 12 Aug 2026.